ANDA 40708, held by Chartwell Molecular. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 40708 (Lidocaine Hydrochloride Viscous), held by Chartwell Molecular, was first approved by FDA on Feb 27, 2007, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Lidocaine hydrochloride oral topical solution USP, 2% (viscous) is indicated for the production of topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. It is also useful for reducing gagging during the taking of X-ray pictures and dental impressions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 27, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride Viscous2% · solution;oral | Lidocaine Hydrochloride | Rx |
| Nov 2, 2018 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 1, 2014 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 27, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters